🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We just published this in The Journal of the American College of Cardiology -- Advances (JACC Advances) "State of the Art Review".   It is a REALLY interesting read, using quotes from Thomas Kuhn's book "The Structure of Scientific Revolutions" (the book that coined the word

📣Announcing Scientific Sessions 2024 Late-Breaking Science 📣 Join us in November to experience the highest tier of scientific discovery and practice-changing educational content. Amit Khera Jo Chikwe

This is a really important paper. STEMI vs Non-STEMI thinking needs to go. It's "occlusion MI" Here is the thing though: almost all of the occlusion MI NSTEMI's can be seen on the ECG--if people could read ECGs properly Table 2 examples seem so obvious to me. Not because I am

In patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT, results of this study found. ja.ma/4dG4O6y

Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? ja.ma/48amoP0

Presented at #AHA24: Among patients with ventricular tachycardia and ischemic cardiomyopathy, catheter ablation as an initial therapy led to a lower risk of adverse outcomes than antiarrhythmic drug therapy. Read the full VANISH2 trial results: nej.md/3Z5ECOD

OPTION trial: After atrial fibrillation ablation, left atrial appendage closure was associated with a lower risk of bleeding than oral anticoagulation and was noninferior to oral anticoagulation with respect to clinical outcomes at 36 months. nej.md/3Oben2U #AHA24

One month of dual antiplatelet therapy (DAPT) followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE among patients with ACS undergoing PCI with DES. ja.ma/4f6myJ2

Precardioversion Assessment With Ct Compared With Tee In Patients With Atrial Fibrillation Or Flutter heartrhythmjournal.com/article/S1547-…

#MachineLearning score to predict in-hospital outcomes in patients hospitalized in Cardiac Intensive Care Unit bit.ly/3BUpkDs #EHJDigital #ArtificialIntelligence Nico Bruining EiC EHJ Digital Health rafavidalperez Folkert Asselbergs ACVCPresident

Drawing on the experience of the first-ever AI software-as-a-medical-device solution successfully approved by regulators, a Case Study discusses lessons learned in overcoming challenges to facilitate the planning of AI solutions in health care settings. nejm.ai/4eVm9cf

Catheter ablation of paroxysmal atrial fibrillation and disease progression: Magnitude of the antiprogression effect and role of intervention timing heartrhythmjournal.com/article/S1547-…

In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: nej.md/3PJcknN #AFib

🫀Hot topic: Can adjunctive posterior wall ablation enhance PVI outcomes in non-paroxysmal AF patients? 💡Check out our latest findings in Heart Rhythm O2! 🔗 doi.org/10.1016/j.hroo… André Rivera Douglas Mesadri Gewehr Andre d’Avila #Cardiology #EPeeps #AtrialFibrillation

Comparison of the Latest ESC, ACC/AHA/ACCP/HRS, and CCS Guidelines on the Management of Atrial Fibrillation | JACC: Clinical Electrophysiology jacc.org/doi/10.1016/j.…

Pulmonary vein isolation (PVI) in persistent AF: not sufficient and possibly not always necessary. Durable PVI increases freedom from AF only in paroxysmal but not in persistent AF Tardu Özkartal @Mbergonti #AHAJournals #Epeeps doi.org/10.1161/CIRCEP…

Lukas Urbanek at the Young Investigator Award about Blanking times in PFA: ➡️ In PFA, too, ERAT predicts long-term recurrence ➡️ 2 months blanking period may be still too long for PFA ➡️ Appropriate blanking time for PFA may be 4 weeks or less EHRAPresident

Adjunctive posterior wall isolation for patients with persistent atrial fibrillation: A systematic review and meta-analysis, by André Rivera, Andre d’Avila, and colleagues UNINOVE UFG UFPR Dignity Health Sac BIDMC #EPeeps heartrhythmopen.com/article/S2666-…

ADVANTAGE AF, the first large prospective study of #PFA to treat PerAF using a PVI and posterior wall isolation strategy, revealed favorable safety and effectiveness outcomes. Get the details: jacc.org/doi/10.1016/j.… #JACC #AFib Vivek Y. Reddy

Most viewed this week from JAMA Cardiology: Cuffless blood pressure (BP) devices face accuracy and regulatory challenges but hold potential for improving BP control if these issues are resolved. ja.ma/3S6V25f